Ultragenyx Pharmaceutical Inc (RARE)
41.19
-0.37
(-0.89%)
USD |
NASDAQ |
May 09, 16:00
41.20
+0.02
(+0.04%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Free Cash Flow (Quarterly): -203.94M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -203.94M |
| December 31, 2023 | -85.50M |
| September 30, 2023 | -121.57M |
| June 30, 2023 | -132.60M |
| March 31, 2023 | -181.90M |
| December 31, 2022 | -117.31M |
| September 30, 2022 | -121.39M |
| June 30, 2022 | -108.18M |
| March 31, 2022 | -179.70M |
| December 31, 2021 | -70.39M |
| September 30, 2021 | -80.21M |
| June 30, 2021 | -85.43M |
| March 31, 2021 | -175.76M |
| December 31, 2020 | -84.40M |
| September 30, 2020 | -65.75M |
| June 30, 2020 | 83.27M |
| March 31, 2020 | -109.25M |
| December 31, 2019 | -83.54M |
| September 30, 2019 | -93.54M |
| June 30, 2019 | -94.30M |
| March 31, 2019 | -98.83M |
| December 31, 2018 | -57.04M |
| September 30, 2018 | -70.19M |
| Date | Value |
|---|---|
| June 30, 2018 | -77.46M |
| March 31, 2018 | -89.95M |
| December 31, 2017 | -82.72M |
| September 30, 2017 | -63.03M |
| June 30, 2017 | -49.20M |
| March 31, 2017 | -61.69M |
| December 31, 2016 | -48.35M |
| September 30, 2016 | -31.75M |
| June 30, 2016 | -44.70M |
| March 31, 2016 | -46.37M |
| December 31, 2015 | -42.37M |
| September 30, 2015 | -32.58M |
| June 30, 2015 | -17.87M |
| March 31, 2015 | -18.12M |
| December 31, 2014 | -12.91M |
| September 30, 2014 | -11.47M |
| June 30, 2014 | -11.22M |
| March 31, 2014 | -11.19M |
| December 31, 2013 | -9.902M |
| September 30, 2013 | -6.95M |
| June 30, 2013 | -8.285M |
| March 31, 2013 | -6.47M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-203.94M
Minimum
Mar 2024
83.27M
Maximum
Jun 2020
-105.57M
Average
-101.24M
Median
Free Cash Flow (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 23.76M |
| Madrigal Pharmaceuticals Inc | -149.51M |
| Sarepta Therapeutics Inc | -284.52M |
| FibroGen Inc | -59.32M |
| Rocket Pharmaceuticals Inc | -58.89M |